Riskpilot← Back to searchSign inGet full accessTOXVÆRD SØLVSMEDJE A/S
A/SActiveCVR 24739716Kronprinsessegade 34B, 1. tvManufacture of jewellery and related articles · NACE 3212Est. 1951— employees
Revenue 2025
DKK 356K
+182% vs 2024
EBITDA margin
100.0%
+182% vs 2024
Equity ratio
86.2%
Financial strength
Net profit 2025
DKK 287K
+192% vs 2024
| Revenue | DKK 356K | +182% |
| EBITDA | DKK 356K | +182% |
| Net profit | DKK 287K | +192% |
| Total assets | DKK 1,2M | +23% |
| Equity | DKK 1M | +19% |
| Employees | — | — |
Legal name
TOXVÆRD SØLVSMEDJE A/S
CVR number
24739716
Legal form
Aktieselskab
NACE code
3212 · Manufacture of jewellery and related articles
Founded
20. november 1951
Share capital
DKK 500.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-05-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør alene, eller af bestyrelsesformanden, eller af to bestyrelsesmedlemmer.
Company purpose
Selskabets formål er at drive handel, fabrikation, investering og dermed beslægtet virksomhed.
Address
Kronprinsessegade 34B, 1. tv
Phone
+4533147126
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 76 | 64 | 83 | 126 | 356 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 76 | 64 | 83 | 126 | 356 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 76 | 64 | 83 | 126 | 356 |
| Net financials | -4 | -6 | -4 | 0 | 0 |
| Profit before tax | 72 | 58 | 79 | 126 | 356 |
| Tax | 16 | 13 | 17 | 28 | 69 |
| Net profit | 56 | 45 | 62 | 98 | 287 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1.023 | 1.025 | 924 | 964 | 1.183 |
| Equity | 995 | 927 | 875 | 855 | 1.020 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 27 | 98 | 50 | 110 | 163 |
| Total debt | 27 | 98 | 50 | 110 | 163 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20212025
Equity ratio
86.2%
This company
38.2%
Market median
+126% vs market
20212025
Return on equity
28.1%
This company
18.4%
Market median
+53% vs market
20212025
Net profit margin
80.6%
This company
8.1%
Market median
+895% vs market
20212025
Asset turnover
0.30×
This company
1.12×
Market median
-73% vs market
20212025
Debt / equity
0.16×
This company
0.62×
Market median
+74% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-06-01 – 2025-05-31
- Annual report 2024Filed via CVR / Virk · Period 2023-06-01 – 2024-05-31
- Annual report 2023Filed via CVR / Virk · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via CVR / Virk · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via CVR / Virk · Period 2020-06-01 – 2021-05-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
KH Management | Management | 1951 – 2004 |
NL Audit | Audit | 1951 – 2007 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2005 | |
| Chairman | 2005 | |
| Board of Directors | 2005 | |
| Former (2) | ||
| Chairman | 1951 – 1989 | |
| Chairman | 2004 – 2005 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 1992 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TOXVÆRD SØLVSMEDJE A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karen Helene Toxværd | Management | 0 companies |
| Niels Lynge Pedersen | Audit | 0 companies |
| Michael Wolter Toxværd | Board of Directors | 0 companies |
| Jette Toxværd | Chairman | 0 companies |
| Martin Toxværd | Board of Directors | 0 companies |
| Svend Toxværd | Chairman | 0 companies |
| Jette Elver Hansen | Chairman | 0 companies |